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Abstract 
Mutations in the SCN1A gene, encoding the neuronal voltage-gated sodium channel 1 
subunit, cause SMEI, GEFS+, and related epileptic syndromes. We herein report the 
R1575C-SCN1A mutation identified in a patient with Rasmussen encephalitis. R1575C 
were constructed in a recombinant human SCN1A and then heterologously expressed in 
HEK293 cells along with the human β1 and β2 sodium channel accessory subunits. 
Whole-cell patch-clamp recording was used to define biophysical properties. The 
R1575C channels exhibited increased channel availability and an increased persistent 
sodium current in comparison to the wild-type. These defects of electrophysiological 
properties can result in neuronal hyperexitability. The seizure susceptibility allele may 
influence the pathogenesis of Rasmussen encephalitis in this case. 
Key words: Rasmussen encephalitis, SCN1A, Genetic-environmental interaction 
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Introduction 
   Rasmussen encephalitis (RE) is an autoimmune-mediated brain disorder associated 
with intractable focal epilepsy, slowly progressive neurological deterioration and 
progressive unilateral hemispheric atrophy (Rasmussen et al., 1958). Serum samples of 
patients with RE contain antibodies to glutamate receptor GluR3, and immunization of 
animals with GluR3 induces a disorder resembling the human disease (Roger et al., 
1994). Histopathological studies have shown an infiltration of T lymphocytes and 
microglia cells, astrocytosis and neuronal loss. A viral infection, humoral autoimmunity 
and T-cell mediated cytotoxicity have been postulated as the possible mechanisms of 
RE (Bien et al, 2005). Although the pathogenesis of RE has not yet been completely 
elucidated, it is widely accepted that environmental factors largely contribute to RE. 
   In contrast to RE, the inherited form of epilepsy is caused by genetic factors. 
Generalized epilepsy with febrile seizures plus (GEFS+) is a familial epilepsy syndrome 
characterized by heterogeneous phenotypes, including febrile seizures, febrile seizures 
plus, and mild to severe epilepsies (Scheffer and Berkovic., 1997). The SCN1A gene, 
which encodes the neuronal voltage-gated sodium channel 1 subunit, has been 
identified in patients with GEFS+, severe myoclonic epilepsy of infancy (SMEI, or 
Dravet syndrome) and related epileptic syndromes. Other undiscovered modifier genes 
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and environmental factors may lead to the wide spectrum of SCN1A-associated 
epilepsies. 
   We herein report the SCN1A-R1575C mutation identified in a patient with 
Rasmussen encephalitis. We found this mutation fortuitously in the process of the 
SCN1A mutational screening of 98 patients having various types of epileptic syndromes. 
The R1575C mutant channels transiently expressed in human embryonic kidney (HEK) 
293 cells exhibited defects of the electrophysiological properties. Since de novo 
mutations of the SCN1A gene have been reported in patients with alleged vaccine 
encephalopathy (Berkovic et al., 2006), we should carefully assess this new aspect of 
genetic-environmental interaction in an autoimmune-mediated brain disorder.
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Materials and Methods 
Patient A 
The patient was a 10-year-old girl and her representative clinical data are shown in 
Fig. 1. Regarding the family history, a febrile seizure occurred in her paternal aunt and 
one of her maternal cousins, respectively (Fig. 1A). She was born after an uneventful 
39-week-long pregnancy with a weight of 3422g. 
She had febrile seizures at 1 year 1 month of age and 1 year 7 months of age. In the 
initial prodromal phase, her development and EEG were both age appropriate. Afebrile 
generalized tonic-clonic seizures (GTCS) began to occur weekly at 2 years of age. Her 
mental development delayed thereafter. Spikes were found in the left frontal region on 
EEG and valproate was started. She had varicella at 2 years 5 months of age. She has 
suffered from myoclonic seizures since 2 years 6 months of age. Her EEG showed 
many spike-and-wave complexes. A battery of examinations, including MRI, CT, 
single-photon emission computed tomography (SPECT) with 99mTc-ECD (ethyl 
cysteinate dimmer) (Fig.1 D-1), CSF, and analyses of chromosome, urinary organic 
acids and lysosomal enzymes, were all normal. The administration of clonazepam 
suppressed the myoclonic seizures and potassium bromide reduced the GTCS. 
At 5 years of age, she had idiopathic thrombocytopenic purpura (ITP). She 
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frequently had focal motor seizures with asymmetric tonic posture. She had a mild gait 
abnormality with less movement in the right arm than in the left at around 5 years of 
age. 
At 8 years of age, right hemiparesis was evident. EEG showed asymmetric slowing 
in the left hemisphere (Fig. 1B) and a cerebral atrophy of the left hemisphere was found 
in MRI (Fig. 1C). She was suspected to have RE, so autoantibodies against GluR2 and 
GluR3 in the serum were analyzed using ELISA. Autoantibodies against GluR3 were 
detected. Her condition has since deteriorated and her IQ (Tanaka-Binet) was 29 at 9 
years of age. SPECT showed hypoperfusion in the left temporoparietal lobes (Fig. 1 
D-2).  
 
Molecular genetic analysis 
SCN1A mutations were analyzed by the previously reported methods (Ohmori et al., 
2002).  
The study was approved by the Ethics Committee of Okayama University Graduate 
School of Medicine, Dentistry, and Pharmaceutical Sciences. Written informed consent 
was obtained from the parents. 
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Mutagenesis and heterologous expression of SCN1A 
   Mutagenesis of full-length human SCN1A cDNA was performed as described 
previously (Lossin et al., 2002). In all of the experiments, recombinant SCN1A was 
heterologously coexpressed with the human β1 and β2 accessory subunits in the 
HEK293 cells.  
 
Electrophysiology and data analysis 
   Whole-cell voltage-clamp recordings were used to characterize the functional 
properties of the wild type (WT)-SCN1A and R1575C mutant sodium channel, as 
described previously (Ohmori et al., 2006). Sodium channel currents were recorded at 
room temperature, 24–72 h after transfection. Patch pipettes were pulled (1.3- 1.9MΩ) 
by multistage P-97 Flaming-Brown micropipette puller. The pipette solution consisted 
of (in mM): 110 CsF, 10 NaF, 20 CsCl, 2 EGTA, 10 HEPES, with a pH of 7.35 and 
osmolarity of 310 mOsmol/kg. The bath solution consisted of (in mM): 145 NaCl, 4 
KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, with a pH of 7.35 and osmolarity of 310 
mOsmol/kg. Specific voltage-clamp protocols assessing channel activation, steady-state 
fast inactivation, recovery from fast inactivation and persistent current were used as 
described previously (Ohmori et al., 2006). The results are presented as the mean ± 
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SEM, and statistical comparisons were made in reference to WT-SCN1A by using the 
unpaired Student’s t-test. The data analysis was performed using the Clampfit 8.2 
(Axon Instruments, Union City, CA, U.S.A.) and OriginPro 7.5 (OriginLab, 
Northampton, MA, U.S.A.) software programs. 
 
Results 
SCN1A mutational analysis 
   The novel R1575C mutation was identified in patient A and her unaffected father 
(Fig. 1E). No other family members agreed to undergo any genetic tests. We did not 
find the R1575C mutation in the healthy individuals (n = 96). 
 
Electrophysiological properties 
   We examined the R1575C mutation for functional defects by using a heterologous 
expression system. Fig. 2A illustrates the representative whole-cell currents recorded 
from the HEK293 cells expressing WT-SCN1A, or R1575C. Cells expressing the 
R1575C mutant exhibited a voltage-dependent inward current which resembled the cells 
transfected with WT channels. The inactivation proceeded in a rapid biexponential 
manner, with no apparent difference between WT and R1575C (Fig. 2B). However, the 
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presence of a persistent sodium current in R1575C was observed. Fig. 2C illustrates the 
representative tetrodotoxin (TTX)-subtracted current traces for both WT-SCN1A and 
R1575C in response to a 100-ms voltage step to−10 mV from a holding potential of 
−120 mV. The cells expressing R1575C exhibited a significantly greater persistent 
current which was expressed as percentage of the peak current in comparison to 
WT-SCN1A (Fig. 2D).  
The current density, voltage-dependence channel activation, inactivation and 
recovery from fast inactivation were examined (Fig. 3). R1575C showed no difference 
for the current density, voltage-dependence channel activation and recovery from fast 
inactivation in comparison to WT. R1575C displayed the most significant defect in fast 
inactivation. R1575C exhibited a slight depolarizing shift in half-maximal steady-state 
inactivation (Fig. 3C). 
 
Discussion 
   The early clinical features of febrile and afebrile convulsions and family history are 
likely to be caused by the SCN1A mutation. The later clinical features also met the 
diagnostic criteria of RE (Bien et al., 2005). She had focal seizures, slowly progressive 
right hemiparesis, mental deterioration, right hemispheric slowing with epileptiform 
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activity on EEG, and right hemispheric atrophy with a gray matter T2/FLAR 
hyperintense signal. There is the possibility that an association between the two 
conditions may be coincidental. 
Regarding the etiology of RE, a direct viral infection, humoral autoimmunity and 
T-cell mediated cytotoxicity have been postulated as the possible mechanisms (Bien et 
al., 2005). The association of RE plus a low grade tumor, cortical dysplasia, tuberous 
sclerosis, or vascular abnormalities have also been described (Bien et al., 2005). More 
than 40% of patients with RE have prior infections, inflammatory episodes or 
vaccinations before the onset of epilepsy (Takahashi et al., 2006). Patient A had 
varicella and ITP around the periods of worsening epilepsy. However, we could not 
identify the exact influence of infectious diseases and ITP because she originally had 
epileptic seizures and the course of the neurological deterioration was slowly 
progressive. 
The R1575C-SCN1A mutation in patient A was carried by her unaffected father. 
However, it was not detected in healthy individuals (n = 96). An electrophysiological 
study showed that the R1575C channels had increased channel availability and 
increased persistent sodium current, which can lead to neuronal hyperexcitability. 
Increased persistent current is a common functional abnormality in SCN1A-associated 
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epileptic syndromes (Lossin et al., 2002, Ohmori et al., 2006). Taken together, these 
findings therefore suggest that R1575C may be a seizure susceptibility allele. The 
seizure susceptibility allele may influence the pathogenesis of Rasmussen encephalitis.  
The spectrum of SCN1A-associated brain disorders has been expanding. The mildest 
form is simple febrile seizure (Mantegazza et al., 2005) and the most severe form is 
SMEI. SCN1A mutations have also been identified in familial hemiplegic migraines 
(Dichgans et al., 2005) and autism (Weiss et al., 2003). Moreover, differences in clinical 
severity among individuals carrying the same mutation are often observed in the GEFS+ 
family and the SMEI family. Factors that are believed to contribute to variable 
expressivity include intrinsic stochastic variability during the development of neuronal 
connectivity in the CNS, the accumulation of somatic mutations over a patient’s lifetime, 
environmental insults, and differences in genetic backgrounds and modifier genes. 
Although the presence of such a susceptibility allele alone is insufficient to cause RE, it 
may exacerbate epileptic seizures when environmental factors are added. The combined 
effect of the SCN1A mutation, yet undiscovered susceptibility genes and the 
autoimmune-response caused by infection or vaccination should be carefully 
considered. 
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Figure legends 
 
Figure 1. Clinical data of patient A.  
(A) The pedigree of patient A. (B) Awake EEG record at 8 years 6 months of age. The 
background activity is slow in the left hemisphere with irregular spike-and-wave 
complexes. (C) MRI showed a left hemispheric mild cerebral atrophy with a gray matter 
T2/FLAR hyperintense signal at 8 years 10 months of age (C-1, T1-weighted image; 
C-2, T2-weighted image, C-3, FLAIR). (D) SPECT was unremarkable at 2 years 10 
months of age (D-1) and showed hypoperfusion in the left parietotemporal lobes at 9 
years 8 months of age (D-2). (E) A mutation analysis of the SCN1A gene. Patient A and 
her father had the R1575C mutation. Numbering of amino acids is given in GenBank 
accession number AB093548. 
 
Figure 2. Sodium currents were recorded from HEK293 cells expressing either 
WT-SCN1A or R1575C. (A) Representative whole-cell sodium currents. The currents 
were activated by voltage steps to between −80 and +60 mV in 20-mV increments from 
a holding potential of −120 mV. (B) Voltage dependence of fast inactivation time 
constants for WT-SCN1A and R1575C. The fast and slow time constants were plotted 
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versus voltage. The whole-cell current inactivation of R1575C is similar toWT-SCN1A. 
(C) Representative tetrodotoxin-subtracted whole-cell sodium currents recorded from 
HEK293 cells expressing WT-SCN1A or R1575C. Each current trace has been 
normalized to its peak sodium current. (D) Average persistent sodium current expressed 
as a percentage of the peak current for WT-SCN1A (0.38% ± 0.10%; n = 7) and 
R1575C (2.12% ± 0.68%; n = 7; p = 0.027). R1575C exhibited a significantly increased 
persistent current in comparison to WT-SCN1A (p < 0.05). 
 
Figure 3. Electrophysical properties of R1575C. (A) Peak current density of whole-cell 
currents elicited by test pulses to various potentials and normalized to cell capacitance. 
Current density of R1575C is similar to WT-SCN1A. (B) Voltage dependence of 
channel activation measured during voltage steps to between −80 and +20 mV from a 
holding potential of −120 mV. Half-maximal activation occurred at -25.9±1.5 mV with 
a slope factor of -6.2 ± 0.3 (n=17) for WT-SCN1A and at -24.6 ± 1.1 mV with a slope 
factor of -6.2 ± 0.2 (n=12) for R1575C. (C) Voltage dependence of fast inactivation 
measured at −10 mV in response to a 100-ms prepulse voltage step to between −140 and 
−10 mV from a holding potential of −120 mV. The membrane potentials for 
half-maximal inactivation and slope factors were as follows: WT, -62.1 ± 1.3 mV and 
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-5.8 ± 0.2, n=15; R1575C, -58.5 ± 1.0 mV (p=0.043) and -6.2 ± 0.3, n=12. (D)
Time-dependent recovery from fast inactivation measured at −10 mV between 1 and 
3,000 ms immediately after a 100-ms prepulse voltage step to −10mV from a holding 
potential of −120 mV. The time constants and fractional amplitudes were as follows: 
WT, f =1.8 ± 0.1 ms (82% ± 1%), s =40.3 ± 5.4 ms (18% ± 1%), n=14; R1575C, 
f =1.8 ± 0.2 ms (79% ± 2%), s =40.8 ± 4.0 ms (21% ± 2%), n=13. There was no 
statistically significant difference between WT and R1575C. 
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